Amalgamated Bank Has $9.52 Million Stock Position in Becton, Dickinson and Company $BDX

Amalgamated Bank lowered its stake in Becton, Dickinson and Company (NYSE:BDX) by 1.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,282 shares of the medical instruments supplier’s stock after selling 775 shares during the period. Amalgamated Bank’s holdings in Becton, Dickinson and Company were worth $9,522,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Bill Few Associates Inc. boosted its position in Becton, Dickinson and Company by 0.7% in the second quarter. Bill Few Associates Inc. now owns 7,906 shares of the medical instruments supplier’s stock valued at $1,362,000 after buying an additional 55 shares in the last quarter. Mendel Money Management boosted its position in Becton, Dickinson and Company by 2.6% in the second quarter. Mendel Money Management now owns 2,254 shares of the medical instruments supplier’s stock valued at $388,000 after buying an additional 58 shares in the last quarter. Stephens Inc. AR boosted its position in Becton, Dickinson and Company by 0.3% in the first quarter. Stephens Inc. AR now owns 18,578 shares of the medical instruments supplier’s stock valued at $4,255,000 after buying an additional 59 shares in the last quarter. Plancorp LLC boosted its position in Becton, Dickinson and Company by 4.1% in the first quarter. Plancorp LLC now owns 1,499 shares of the medical instruments supplier’s stock valued at $343,000 after buying an additional 59 shares in the last quarter. Finally, Moody National Bank Trust Division boosted its position in Becton, Dickinson and Company by 2.4% in the second quarter. Moody National Bank Trust Division now owns 2,586 shares of the medical instruments supplier’s stock valued at $445,000 after buying an additional 60 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on BDX. Royal Bank Of Canada restated a “sector perform” rating and issued a $211.00 target price on shares of Becton, Dickinson and Company in a research report on Thursday, October 16th. Piper Sandler restated a “neutral” rating and issued a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Morgan Stanley increased their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Finally, Wells Fargo & Company increased their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a report on Friday, August 8th. Three research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $205.40.

Becton, Dickinson and Company Price Performance

BDX stock opened at $179.07 on Friday. The firm has a market cap of $51.33 billion, a price-to-earnings ratio of 32.21, a PEG ratio of 1.42 and a beta of 0.25. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The company’s fifty day simple moving average is $188.79 and its 200 day simple moving average is $183.36.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. The business had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. On average, analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Claire Fraser sold 917 shares of the stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the transaction, the director owned 22,226 shares of the company’s stock, valued at $4,167,375. This represents a 3.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold 1,895 shares of company stock valued at $358,995 over the last ninety days. Insiders own 0.36% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.